Cancer–neuronal crosstalk and the startups working to silence it
Elie Dolgin • February 7, 2020
Investors back ‘cancer neuroscience’ outfits as the field breaks out from academia.
Continue reading here.
Fresh treatments shift the focus from symptom management to repair.
Smart algorithms take aim at antimicrobial resistance.